<DOC>
	<DOCNO>NCT00128297</DOCNO>
	<brief_summary>The study objective evaluate difference , term first occurrence skeletal event , patient breast cancer symptomatic bone metastasis , pamidronate administer 2 year , administer 6 month , follow six month rest period , 6 month treatment period .</brief_summary>
	<brief_title>Pamidronate Administration Breast Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>Written inform consent . Up two previous current hormone therapy treatment metastatic breast cancer allow . Normal borderline renal function ( serum creatinine &lt; 1.5 x upper normal limit [ UNL ] ) . Normal calcium level serum , slightly nonsymptomatic high level ( &lt; 1.25 x UNL ) . Performance status 0 , I II WHO scale . Treatment bisphosphonates 30 previous day , time indication treatment metastatic bone lesion . Treatment bisphosphonates allow indication hypercalcaemia . Metastases central nervous system ( CNS ) . Hypersensitivity bisphosphonates component formula . Pregnant lactating woman . Previous current treatment second chemotherapy line third hormone therapy line metastatic disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Breast cancer patient symptomatic bone metastasis</keyword>
</DOC>